These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3138789)

  • 1. Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmoset.
    Eason CT; Spencer AJ; Pattison A; Howells DD; Henry DC; Bonner FW
    Toxicol Appl Pharmacol; 1988 Sep; 95(2):328-38. PubMed ID: 3138789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate.
    Spencer AJ; Barbolt TA; Henry DC; Eason CT; Sauerschell RJ; Bonner FW
    Toxicol Pathol; 1989; 17(1 Pt 1):7-15. PubMed ID: 2501865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The peroxisome-proliferator ciprofibrate induces hypergastrinemia without raising gastric pH.
    Martinsen TC; Nesjan N; Rønning K; Sandvik AK; Waldum HL
    Carcinogenesis; 1996 Oct; 17(10):2153-5. PubMed ID: 8895482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of gastric antisecretory effects of phenoxyisobutyrate derivatives in the rat and the mouse.
    Eason CT; Pattison A; Howells DD; Spencer AJ; Bonner FW
    Scand J Gastroenterol; 1988 Nov; 23(9):1063-71. PubMed ID: 3247588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset.
    Makowska JM; Bonner FW; Gibson GG
    Arch Toxicol; 1991; 65(2):106-13. PubMed ID: 1905530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ciprofibrate on gastric secretion in the rat.
    Eason CT; Pattison A; Howells DD; Bonner FW
    J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antral G cells in rats during dosing with a PPAR alpha agonist: a morphometric and immunocytochemical study.
    Martinsen TC; Skogaker NE; Bendheim MØ; Waldum HL
    Med Electron Microsc; 2003 Mar; 36(1):18-32. PubMed ID: 12658348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
    Makowska JM; Anders C; Goldfarb PS; Bonner F; Gibson GG
    Biochem Pharmacol; 1990 Sep; 40(5):1083-93. PubMed ID: 2390105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell.
    Waldum HL; Kvetnoi IM; Sylte R; Schulze B; Martinsen TC; Sandvik AK
    J Mol Endocrinol; 1998 Feb; 20(1):111-7. PubMed ID: 9513087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat.
    Eason CT; Powles P; Henry G; Spencer AJ; Pattison A; Bonner FW
    Xenobiotica; 1989 Aug; 19(8):913-25. PubMed ID: 2815833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPAR alpha stimulates the rat gastrin-producing cell.
    Bakke I; Hammer TA; Sandvik AK; Waldum HL
    Mol Cell Endocrinol; 2002 Sep; 195(1-2):89-97. PubMed ID: 12354675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of liver cell proliferation during ciprofibrate-induced hepatocarcinogenesis.
    Yeldandi AV; Milano M; Subbarao V; Reddy JK; Rao MS
    Cancer Lett; 1989 Sep; 47(1-2):21-7. PubMed ID: 2636030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of gamma-glutamyltranspeptidase activity in lung metastasis in rats with hepatocellular carcinomas induced by ciprofibrate, a peroxisome proliferator.
    Milano M; Reddy JK; Prasad JD; Rao MS
    Cancer Lett; 1987 Dec; 38(1-2):65-71. PubMed ID: 2891433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
    Awasthi YC; Singh SV; Goel SK; Reddy JK
    Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of initiating activity of the peroxisome proliferator ciprofibrate in two-stage hepatocarcinogenesis.
    Glauert HP; Clark TD
    Cancer Lett; 1989 Feb; 44(2):95-100. PubMed ID: 2920376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased resistance of peroxisome proliferator-induced hepatic lesions to iron overload in rats.
    Rao MS; Subbarao V; Reddy JK
    Cancer Lett; 1986 Jul; 32(1):33-9. PubMed ID: 3742486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relative hypolipidaemic activity and hepatic effects of ciprofibrate enantiomers in the rat.
    Graham MJ; Winham MA; Harpur ES; Bonner FW; Gray TJ
    Biochem Pharmacol; 1994 Dec; 48(12):2163-71. PubMed ID: 7811297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gamma-Glutamyltranspeptidase-negative phenotypic property of preneoplastic and neoplastic liver lesions induced by ciprofibrate does not change following 2-acetylaminofluorene administration.
    Yeldandi AV; Subbarao V; Rajan A; Reddy JK; Rao MS
    Carcinogenesis; 1989 Apr; 10(4):797-9. PubMed ID: 2564815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.